HIV and AIDs II Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Cytopathic, especially late in infection

A

HIV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Cells infected by ‘late’ virus form syncytia which later die. Syncytium formation results from binding of SU/TM on infected cell plasma membranes to

A

CD4 membranes of other cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

This triggers membrane fusion just as during virus infection, and allows virus to spread between cells without exposure to

A

Antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

HIV regulatory proteins, especially nef, have been reported to have

A

Toxic effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Blocks repair of DNA damage and un-repaired DNA may trigger apoptosis

A

Vpu

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Most dying T cells are not infected with

A

HIV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Characterized by persistent high-level proliferation and activity of all types of immune cells and overproduction of their products (Ig, cytokines)

A

HIV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

This may favor virus replication which is more efficient in activated T cells, and/or lead to ‘activation-induced death’ of lymphocytes as they become progressively more susceptible to

A

Apoptosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Soluble SU protein can deliver signals through CD4 and CCR which may also favor

A

Apoptosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

One mechanism by which HIV may escape the immune system is failure of the persistence of

A

CD8 anti-HIV clones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Preferential infection of anti-HIV clones of CD4+ cells may also allow

A

HIV to evade immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MHC heterozygosity and response to numerous HIV epitopes both slow the progression of

A

HIV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

“Co-factors” such as infections with other pathogens increase the rate of transcription from the HIV LTR by activating

A

T-cell transcription factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

For example, development of active tuberculosis increases

A

Plasma viremia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Progressive exhaustion of the immune system may eventually decrease CD4+ cell numbers to the point that immunity cannot be maintained, setting the stage for high-level

A

Viral multiplications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Chronic exposure of T cells to antigen leads to appearance of membrane receptors (CD38, PD-1) that decrease their

A

Function

17
Q

Blockade of these receptors may be a promising approach to restoring immune control of

A

HIV

18
Q

Lacks the proofreading capacity of cellular DNA polymerases and has a high mutation rate, roughly 10-3 per nucleotide

A

Reverse transcriptase

19
Q

The transition from the asymptomatic period to AIDS is marked by a shift in co-receptor use and in

A

Cell tropism

20
Q

Initially HIV uses CCR5. Late in infection, virus variants appear which use CXCR4 and are highly-cytopathic for

A

T cells

21
Q

What is the standard screening process for HIV?

A

ELISA, then if positive, ELISA is repeated and confirmed by Western blot

22
Q

PCR tests are very sensitive and can be useful if Western Blots are ambiguous, but their sensitivity renders them prone to

A

False positives

23
Q

What is the current treatment for HIV?

A

Use of 2 nucleoside RT inhibitors plus a non-nucleoside RT inhibitor or protease inhibitor

24
Q

Chosen so that mutations which confer resistance to one drug do not create resistance to another

A

RT inhibitors

25
Q

Integrase inhibitors and CCR5 Chemokine receptor antagonists have recently been

A

FDA-approved

26
Q

Mediates fusion of the viral envelope with the plasma membrane and contains a pair of α-helices which undergo two shifts in conformation

A

HIV TM

27
Q

The first shift exposes a hydrophobic fusion peptide which inserts into the

A

Host cell membrane

28
Q

The second brings viral and host membranes close together, as a prelude to

-Requires lateral association of α-helices

A

Fusion

29
Q

A synthetic α-helical peptide that binds to the intermediate conformation of TM, prevents the second shift, and blocks fusion

A

T-20

30
Q

In clinical trials it reduced viral load by about 100x and is FDA-approved

A

T-20

31
Q

For patients with low CD4 count, we want to give prophylaxis against Pneumocystis carinii pneumonia. For this, we give

A

TMP-SMX

32
Q

Can cause lipid redistribution and are linked to heart attacks

A

Protease inhibitors

33
Q

Nucleoside RT inhibitors can be

A

Nephrotoxic

34
Q

Indicates the patients current stage of disease

A

CD4 level

35
Q

Predicts how rapidly a patient’s disease is likely to progress

A

Viral load

36
Q

SU protein, the target of neutralizing antibodies, is heavily glycosylated, which shields most epitopes from

A

Antibodies

37
Q

Bind to a surface loop of SU, but this can rapidly develop amino acid substitutions which render existing antibodies ineffective

A

Neutralizing anti-bodies